# A Study of Olverembatinib in SDH-deficient GIST.

Source: https://onco.cc/trials/nct06640361/  
OnCo record `nct06640361` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Olverembatinib run by Ascentage Pharma Group Inc., now recruiting.

## Summary

A Study of Olverembatinib in SDH-deficient GIST. is a phase 3 interventional study registered as NCT06640361 by Ascentage Pharma Group Inc., with 40 participants planned, started 2024-11-11. Conditions listed: GIST. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06640361
- Phase: 3
- Setting: A Single-Arm Registrational Phase III Study of Olverembatinib in the Treatment of Patients With SDH-Deficient Gastrointestinal Stromal Tumor (POLARIS-3)
- Sponsor: Ascentage Pharma Group Inc.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT06640361: https://clinicaltrials.gov/study/NCT06640361

## Connected records

- drugs: [Olverembatinib](https://onco.cc/drugs/olverembatinib/)
- companies: [Ascentage Pharma](https://onco.cc/companies/ascentage-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct06640361.json